Ulipristal Acetate [For emergency contraception] interactions
Checked as Ulipristal in this data source.
Full monograph for Ulipristal Acetate [For emergency contraception]Check it against another medicine
Medicines
142 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Apalutamide | Major | Metabolism | Coadministration with potent and moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of ulipristal acetate and its… | 6 sources — open the full entry |
| Calcium Dobesilate + Lidocaine + Dexamethasone | Major | Metabolism | Coadministration with potent and moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of ulipristal acetate and its… | 6 sources — open the full entry |
| Cenobamate | Major | Metabolism | Coadministration with potent and moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of ulipristal acetate and its… | 6 sources — open the full entry |
| Ciprofloxacin + Dexamethasone | Major | Metabolism | Coadministration with potent and moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of ulipristal acetate and its… | 6 sources — open the full entry |
| Colchicine | Major | Excretion | Coadministration with inhibitors of P-glycoprotein (P-gp) may significantly increase the serum concentrations of colchicine. The mechanism involves enhanced… | 78 sources — open the full entry |
| Dexamethasone | Major | Metabolism | Coadministration with potent and moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of ulipristal acetate and its… | 6 sources — open the full entry |
| Dexamethasone + Chloramphenicol | Major | Metabolism | Coadministration with potent and moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of ulipristal acetate and its… | 6 sources — open the full entry |
| Dexamethasone + Levofloxacin | Major | Metabolism | Coadministration with potent and moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of ulipristal acetate and its… | 6 sources — open the full entry |
| Dexamethasone + Neomycin + Glacial Acetic Acid | Major | Metabolism | Coadministration with potent and moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of ulipristal acetate and its… | 6 sources — open the full entry |
| Dexamethasone + Neomycin Sulphate + Polymyxin B Sulphate | Major | Metabolism | Coadministration with potent and moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of ulipristal acetate and its… | 6 sources — open the full entry |
| Dexamethasone + Tobramycin | Major | Metabolism | Coadministration with potent and moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of ulipristal acetate and its… | 6 sources — open the full entry |
| Enzalutamide | Major | Metabolism | Coadministration with potent and moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of ulipristal acetate and its… | 6 sources — open the full entry |
| Gatifloxacin + Dexamethasone | Major | Metabolism | Coadministration with potent and moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of ulipristal acetate and its… | 6 sources — open the full entry |
| Moxifloxacin Hydrochloride + Dexamethasone | Major | Metabolism | Coadministration with potent and moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of ulipristal acetate and its… | 6 sources — open the full entry |
| Sotorasib | Major | Metabolism | Coadministration with potent and moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of ulipristal acetate and its… | 6 sources — open the full entry |
| Venetoclax | Major | Absorption | Coadministration with P-glycoprotein (P-gp) inhibitors may increase the plasma concentrations of venetoclax, which is a substrate of this efflux transporter. | 5 sources — open the full entry |
| Abametapir | Moderate | Metabolism | Based on in vitro inhibition data, a single topical application of abametapir lotion may increase plasma concentrations of drugs that are substrates of CYP450… | 1 sources — open the full entry |
| Afatinib Dimaleate | Moderate | Others | Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of afatinib, which is a substrate of the efflux transporter. | 4 sources — open the full entry |
| Ambrisentan | Moderate | Others | Based on in vitro inhibition data, coadministration with ulipristal may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein… | 1 sources — open the full entry |
| Apixaban | Moderate | Metabolism | Coadministration with inhibitors of CYP450 3A4 and/or P-glycoprotein (P-gp) may increase the plasma concentrations of apixaban, which is a substrate of both… | 2 sources — open the full entry |
| Armodafinil | Moderate | Metabolism | The concomitant use of CYP450 3A4 inducers may decrease the plasma concentrations and efficacy of ulipristal, which is primarily metabolized by the isoenzyme… | 12 sources — open the full entry |
| Artesunate | Moderate | Others | Based on in vitro inhibition data, coadministration with ulipristal may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein… | 1 sources — open the full entry |
| Betrixaban | Moderate | Others | Based on in vitro inhibition data, coadministration with ulipristal may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein… | 1 sources — open the full entry |
| Bosentan Monohydrate | Moderate | Metabolism | The concomitant use of CYP450 3A4 inducers may decrease the plasma concentrations and efficacy of ulipristal, which is primarily metabolized by the isoenzyme… | 12 sources — open the full entry |
| Carbamazepine | Moderate | Metabolism | The concomitant use of CYP450 3A4 inducers may decrease the plasma concentrations and efficacy of ulipristal, which is primarily metabolized by the isoenzyme… | 12 sources — open the full entry |
| Ceritinib | Moderate | Others | Based on in vitro inhibition data, coadministration with ulipristal may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein… | 1 sources — open the full entry |
| Cyclosporine (Oral) | Moderate | Others | Based on in vitro inhibition data, coadministration with ulipristal may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein… | 1 sources — open the full entry |
| Dabigatran Etexilate Mesylate | Moderate | Metabolism | Based on in vitro inhibition data, coadministration with ulipristal may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein… | 1 sources — open the full entry |
| Daunorubicin | Moderate | Absorption | Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of daunorubicin and idarubicin, both of which are substrates… | 5 sources — open the full entry |
| Deferasirox | Moderate | Metabolism | The concomitant use of CYP450 3A4 inducers may decrease the plasma concentrations and efficacy of ulipristal, which is primarily metabolized by the isoenzyme… | 12 sources — open the full entry |
| Desogestrel | Moderate | Antagonism | RECOMMENDED: Coadministration of ulipristal with combination hormonal contraceptives may reduce the efficacy of both treatments for the prevention of…2 documented mechanisms | 6 sources — open the full entry |
| Dienogest | Moderate | Antagonism | RECOMMENDED: Coadministration of ulipristal with combination hormonal contraceptives may reduce the efficacy of both treatments for the prevention of…2 documented mechanisms | 6 sources — open the full entry |
| Dienogest + Estradiol Valerate | Moderate | Antagonism | RECOMMENDED: Coadministration of ulipristal with combination hormonal contraceptives may reduce the efficacy of both treatments for the prevention of…2 documented mechanisms | 6 sources — open the full entry |
| Digoxin | Moderate | Others | Based on in vitro inhibition data, coadministration with ulipristal may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein… | 1 sources — open the full entry |
| Docetaxel Trihydrate | Moderate | Others | Based on in vitro inhibition data, coadministration with ulipristal may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein… | 1 sources — open the full entry |
| Doxorubicin Hydrochloride | Moderate | Others | Based on in vitro inhibition data, coadministration with ulipristal may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein… | 1 sources — open the full entry |
| Doxorubicin Hydrochloride Liposome | Moderate | Others | Based on in vitro inhibition data, coadministration with ulipristal may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein… | 1 sources — open the full entry |
| Drospirenone | Moderate | Antagonism | RECOMMENDED: Coadministration of ulipristal with combination hormonal contraceptives may reduce the efficacy of both treatments for the prevention of… | 4 sources — open the full entry |
| Drospirenone + Estetrol | Moderate | Antagonism | RECOMMENDED: Coadministration of ulipristal with combination hormonal contraceptives may reduce the efficacy of both treatments for the prevention of… | 4 sources — open the full entry |
| Drospirenone + Estradiol | Moderate | Antagonism | RECOMMENDED: Coadministration of ulipristal with combination hormonal contraceptives may reduce the efficacy of both treatments for the prevention of… | 4 sources — open the full entry |
| Drospirenone + Ethinyl Estradiol0.02 mg0.03 mg | Moderate | Antagonism | RECOMMENDED: Coadministration of ulipristal with combination hormonal contraceptives may reduce the efficacy of both treatments for the prevention of… | 4 sources — open the full entry |
| Drospirenone + Ethinyl Estradiol + Levomefolate | Moderate | Antagonism | RECOMMENDED: Coadministration of ulipristal with combination hormonal contraceptives may reduce the efficacy of both treatments for the prevention of… | 4 sources — open the full entry |
| Efavirenz | Moderate | Metabolism | The concomitant use of CYP450 3A4 inducers may decrease the plasma concentrations and efficacy of ulipristal, which is primarily metabolized by the isoenzyme… | 12 sources — open the full entry |
| Elagolix Sodium | Moderate | Metabolism | Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ulipristal acetate and its pharmacologically active metabolite. Based on… | 4 sources — open the full entry |
| Epirubicin Hydrochloride | Moderate | Others | Based on in vitro inhibition data, coadministration with ulipristal may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein… | 1 sources — open the full entry |
| Erlotinib | Moderate | Others | Based on in vitro inhibition data, coadministration with ulipristal may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein… | 1 sources — open the full entry |
| Ethinyl Estradiol + Desogestrel0.02 mg0.03 mg | Moderate | Antagonism | RECOMMENDED: Coadministration of ulipristal with combination hormonal contraceptives may reduce the efficacy of both treatments for the prevention of…2 documented mechanisms | 6 sources — open the full entry |
| Ethinyl Estradiol + Levonorgestrel + Ferrous Fumarate | Moderate | Antagonism | RECOMMENDED: Coadministration with ulipristal may reduce the efficacy of combination hormonal contraceptives. There are no clinical data regarding use of… | 36 sources — open the full entry |
| Etoposide | Moderate | Others | Based on in vitro inhibition data, coadministration with ulipristal may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein… | 1 sources — open the full entry |
| Everolimus | Moderate | Absorption | Coadministration with inhibitors of CYP450 3A4 and/or P-glycoprotein may increase the blood concentrations of everolimus following oral administration… | 4 sources — open the full entry |
Conditions
Conditions in which Ulipristal Acetate [For emergency contraception] needs care, as documented in this source.
Hepatic Insufficiency
ModerateNo studies have been conducted to evaluate the effect of hepatic disease on the disposition of ulipristal. Caution is recommended when using this agent in patients with liver disease.
1 source
- "Product Information. Ella (ulipristal)." Afaxys Inc. (2022):
Kidney Diseases
ModerateNo studies have been conducted to evaluate the effect of renal disease on the disposition of ulipristal. Caution is recommended when using this agent in patients with renal impairment.
1 source
- "Product Information. Ella (ulipristal)." Afaxys Inc. (2022):